Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hibercell Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are housed within 1 distinct art unit, suggesting a consistent technical classification for the company's current filings. This centralization within a single art unit allows for a prosecution strategy that accounts for the specific technical expertise and internal guidelines of that unit. The involvement of 2 distinct examiners, however, means that the company must still account for individual differences in how these examiners interpret the prior art.
ROBERT H HAVLIN is the busiest examiner for the portfolio with 1 pending office action. Since the total pending count is 2, the workload is split evenly between the examiners, preventing any single individual from dominating the company's current prosecution strategy. Practitioners should monitor whether these examiners maintain consistent positions on similar claims, given that they are operating within the same art unit on the company's biotechnology applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262493 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HERNANDEZ, JACKSON J | 70d overdue |
| 18869103 | GCN2 MODULATOR FOR TREATING CANCER | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18869103 | GCN2 MODULATOR FOR TREATING CANCER | HAVLIN, ROBERT H | — | §112DP | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18262493 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HERNANDEZ, JACKSON J | 1627 | DP | Final Rejection | 70d overdue | Pending | Jul 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial